AI Article Synopsis
- The review focuses on the potential of miRNAs as diagnostic and prognostic biomarkers for cancer and their use as therapeutics.
- Blood-based exosomal miRNAs are highlighted for their stability and ease of analysis, but there is a lack of consensus in research findings.
- Challenges remain in using miRNAs as treatments due to off-target effects, although advancements in nanotechnology may improve targeted delivery and reduce toxicity.
Article Abstract
Purpose Of Review: The goals of this review are to examine the usefulness of miRNAs as diagnostic and prognostic biomarkers for cancer and to evaluate the applicability of miRNAs as cancer therapeutics.
Recent Findings: Examination of miRNA milieu from body fluids offers a new alternative for quick, affordable and easy analysis of disease status in patients. Blood-based exosomal miRNAs have increased stability and are an excellent choice for clinical cancer diagnostics and prognostics. Currently, there are many miRNA signatures associated with cancer and progression but there is no consensus among multiple sera and tumor sample studies. Off-target and immunological effects remains an obstacle for use of miRNAs as novel chemotherapeutics in the clinic. Recent developments in nanotechnology and drug delivery systems which target the tumor microenvironment may provide an alternative therapeutic approach with decreased toxicity.
Summary: This review critically evaluates the literature investigating the use of miRNAs as biomarkers and their future as potential therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613763 | PMC |
| http://dx.doi.org/10.1007/s40139-017-0123-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!